Titre : Échelle visuelle analogique

Échelle visuelle analogique : Questions médicales fréquentes

Termes MeSH sélectionnés :

beta-Cyclodextrins
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Échelle visuelle analogique : Questions médicales les plus fréquentes", "headline": "Échelle visuelle analogique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Échelle visuelle analogique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-24", "dateModified": "2025-04-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Échelle visuelle analogique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Techniques et procédures diagnostiques", "url": "https://questionsmedicales.fr/mesh/D019937", "about": { "@type": "MedicalCondition", "name": "Techniques et procédures diagnostiques", "code": { "@type": "MedicalCode", "code": "D019937", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E01.370" } } }, "about": { "@type": "MedicalCondition", "name": "Échelle visuelle analogique", "alternateName": "Visual Analog Scale", "code": { "@type": "MedicalCode", "code": "D064232", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Andrea Coda", "url": "https://questionsmedicales.fr/author/Andrea%20Coda", "affiliation": { "@type": "Organization", "name": "School of Health Sciences, Faculty of Health and Medicine, The University of Newcastle, Ourimbah, Australia." } }, { "@type": "Person", "name": "Benedict U Nwachukwu", "url": "https://questionsmedicales.fr/author/Benedict%20U%20Nwachukwu", "affiliation": { "@type": "Organization", "name": "Division of Sports Medicine Surgery, Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois, U.S.A." } }, { "@type": "Person", "name": "Carles Escalona-Marfil", "url": "https://questionsmedicales.fr/author/Carles%20Escalona-Marfil", "affiliation": { "@type": "Organization", "name": "Facultat de Ciències de la Salut de Manresa, Universitat de Vic-Universitat Central de Catalunya, Manresa, Spain." } }, { "@type": "Person", "name": "Jorge Ruiz-Moreno", "url": "https://questionsmedicales.fr/author/Jorge%20Ruiz-Moreno", "affiliation": { "@type": "Organization", "name": "MIXESTAT SL, Barcelona, Spain." } }, { "@type": "Person", "name": "Xavier Gironès", "url": "https://questionsmedicales.fr/author/Xavier%20Giron%C3%A8s", "affiliation": { "@type": "Organization", "name": "Facultat de Ciències de la Salut de Manresa, Universitat de Vic-Universitat Central de Catalunya, Manresa, Spain." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Phenotypic Expression of Known and Novel Hemoglobin A2-Variants, Hemoglobin A2-Mae Phrik [Delta 52(D3) Asp > Gly, HBD:c.158A > G], Associated with Hemoglobin E [Beta 26(B8) Glu > Lys, HBB:c.79G > A] in Thailand", "datePublished": "2022-05-27", "url": "https://questionsmedicales.fr/article/35741722", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/genes13060959" } }, { "@type": "ScholarlyArticle", "name": "Clinical Efficacy and Safety of Early Intravenous Administration of Beta-Blockers in Patients Suffering from Acute ST-Segment Elevation Myocardial Infarction Without Heart Failure Undergoing Primary Percutaneous Coronary Intervention: A Study-Level Meta-Analysis of Randomized Clinical Trials.", "datePublished": "2023-04-01", "url": "https://questionsmedicales.fr/article/37002468", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10557-023-07448-x" } }, { "@type": "ScholarlyArticle", "name": "Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.", "datePublished": "2024-06-12", "url": "https://questionsmedicales.fr/article/38878794", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S2666-5247(24)00078-8" } }, { "@type": "ScholarlyArticle", "name": "Review of concerned SARS-CoV-2 variants like Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529), as well as novel methods for reducing and inactivating SARS-CoV-2 mutants in wastewater treatment facilities.", "datePublished": "2022-08-04", "url": "https://questionsmedicales.fr/article/37520798", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.hazadv.2022.100140" } }, { "@type": "ScholarlyArticle", "name": "Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.", "datePublished": "2023-09-29", "url": "https://questionsmedicales.fr/article/37783221", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S2666-5247(23)00177-5" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Diagnostic", "item": "https://questionsmedicales.fr/mesh/D003933" }, { "@type": "ListItem", "position": 3, "name": "Techniques et procédures diagnostiques", "item": "https://questionsmedicales.fr/mesh/D019937" }, { "@type": "ListItem", "position": 4, "name": "Échelle visuelle analogique", "item": "https://questionsmedicales.fr/mesh/D064232" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Échelle visuelle analogique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Échelle visuelle analogique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Échelle visuelle analogique", "description": "Comment l'EVA est-elle utilisée pour le diagnostic ?\nL'EVA est-elle fiable pour tous les patients ?\nQuels types de douleurs l'EVA évalue-t-elle ?\nL'EVA peut-elle être utilisée pour d'autres sensations ?\nQuelle est l'échelle de l'EVA ?", "url": "https://questionsmedicales.fr/mesh/D064232?mesh_terms=beta-Cyclodextrins&page=508#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Échelle visuelle analogique", "description": "Quels symptômes l'EVA peut-elle aider à évaluer ?\nL'EVA peut-elle refléter des symptômes psychologiques ?\nComment l'EVA aide-t-elle à suivre l'évolution des symptômes ?\nL'EVA est-elle sensible aux variations des symptômes ?\nPeut-on utiliser l'EVA pour des douleurs non physiques ?", "url": "https://questionsmedicales.fr/mesh/D064232?mesh_terms=beta-Cyclodextrins&page=508#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Échelle visuelle analogique", "description": "L'EVA peut-elle aider à prévenir la douleur ?\nComment l'EVA est-elle intégrée dans les programmes de prévention ?\nPeut-on utiliser l'EVA pour prévenir les douleurs chroniques ?\nL'EVA est-elle utile dans la rééducation préventive ?\nL'EVA peut-elle être utilisée dans des programmes de sensibilisation ?", "url": "https://questionsmedicales.fr/mesh/D064232?mesh_terms=beta-Cyclodextrins&page=508#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Échelle visuelle analogique", "description": "Comment l'EVA influence-t-elle les choix de traitement ?\nL'EVA est-elle utilisée pour évaluer l'efficacité des traitements ?\nQuels traitements peuvent être évalués par l'EVA ?\nL'EVA peut-elle aider à ajuster les doses de médicaments ?\nL'EVA est-elle utilisée dans les soins palliatifs ?", "url": "https://questionsmedicales.fr/mesh/D064232?mesh_terms=beta-Cyclodextrins&page=508#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Échelle visuelle analogique", "description": "Quelles complications peuvent survenir sans évaluation de la douleur ?\nL'EVA peut-elle aider à prévenir des complications liées à la douleur ?\nComment l'EVA aide-t-elle à identifier des complications ?\nL'EVA est-elle utile pour évaluer des complications postopératoires ?\nQuelles complications psychologiques peuvent être évaluées par l'EVA ?", "url": "https://questionsmedicales.fr/mesh/D064232?mesh_terms=beta-Cyclodextrins&page=508#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Échelle visuelle analogique", "description": "Quels facteurs de risque influencent l'évaluation de la douleur ?\nL'EVA prend-elle en compte les différences culturelles ?\nComment le stress affecte-t-il l'EVA ?\nLes antécédents médicaux influencent-ils l'EVA ?\nL'EVA est-elle sensible aux facteurs psychologiques ?", "url": "https://questionsmedicales.fr/mesh/D064232?mesh_terms=beta-Cyclodextrins&page=508#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment l'EVA est-elle utilisée pour le diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'EVA aide à quantifier la douleur, facilitant le diagnostic des affections douloureuses." } }, { "@type": "Question", "name": "L'EVA est-elle fiable pour tous les patients ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'EVA est généralement fiable, mais peut être moins précise chez les jeunes enfants ou les personnes âgées." } }, { "@type": "Question", "name": "Quels types de douleurs l'EVA évalue-t-elle ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'EVA évalue les douleurs aiguës, chroniques et postopératoires." } }, { "@type": "Question", "name": "L'EVA peut-elle être utilisée pour d'autres sensations ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'EVA peut également mesurer l'anxiété, la fatigue et d'autres sensations subjectives." } }, { "@type": "Question", "name": "Quelle est l'échelle de l'EVA ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'EVA est généralement une ligne de 10 cm, où 0 représente aucune douleur et 10 la douleur maximale." } }, { "@type": "Question", "name": "Quels symptômes l'EVA peut-elle aider à évaluer ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "L'EVA évalue principalement la douleur, mais peut aussi mesurer l'inconfort et la détresse." } }, { "@type": "Question", "name": "L'EVA peut-elle refléter des symptômes psychologiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'EVA peut être utilisée pour évaluer des symptômes psychologiques comme l'anxiété." } }, { "@type": "Question", "name": "Comment l'EVA aide-t-elle à suivre l'évolution des symptômes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "L'EVA permet de comparer les niveaux de douleur au fil du temps, facilitant le suivi des traitements." } }, { "@type": "Question", "name": "L'EVA est-elle sensible aux variations des symptômes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'EVA est sensible aux changements, permettant d'évaluer l'efficacité des interventions." } }, { "@type": "Question", "name": "Peut-on utiliser l'EVA pour des douleurs non physiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'EVA peut évaluer des douleurs émotionnelles ou psychologiques, comme la tristesse." } }, { "@type": "Question", "name": "L'EVA peut-elle aider à prévenir la douleur ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Indirectement, en identifiant les douleurs précoces, l'EVA peut guider les mesures préventives." } }, { "@type": "Question", "name": "Comment l'EVA est-elle intégrée dans les programmes de prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'EVA est utilisée pour évaluer les douleurs liées à des activités spécifiques, permettant d'adapter les programmes." } }, { "@type": "Question", "name": "Peut-on utiliser l'EVA pour prévenir les douleurs chroniques ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une évaluation précoce avec l'EVA peut aider à prévenir l'évolution vers des douleurs chroniques." } }, { "@type": "Question", "name": "L'EVA est-elle utile dans la rééducation préventive ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'EVA aide à évaluer la douleur pendant la rééducation, permettant d'ajuster les exercices." } }, { "@type": "Question", "name": "L'EVA peut-elle être utilisée dans des programmes de sensibilisation ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'EVA peut sensibiliser les patients à l'importance de l'évaluation de la douleur." } }, { "@type": "Question", "name": "Comment l'EVA influence-t-elle les choix de traitement ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "L'EVA guide les médecins dans le choix des traitements en fonction de l'intensité de la douleur." } }, { "@type": "Question", "name": "L'EVA est-elle utilisée pour évaluer l'efficacité des traitements ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'EVA permet de mesurer l'amélioration de la douleur après un traitement." } }, { "@type": "Question", "name": "Quels traitements peuvent être évalués par l'EVA ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'EVA peut évaluer l'efficacité des médicaments, thérapies physiques et interventions chirurgicales." } }, { "@type": "Question", "name": "L'EVA peut-elle aider à ajuster les doses de médicaments ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'EVA aide à ajuster les doses en fonction de la réponse du patient à la douleur." } }, { "@type": "Question", "name": "L'EVA est-elle utilisée dans les soins palliatifs ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'EVA est couramment utilisée pour gérer la douleur des patients en soins palliatifs." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir sans évaluation de la douleur ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Sans évaluation, les patients peuvent souffrir de douleurs non traitées, entraînant des complications." } }, { "@type": "Question", "name": "L'EVA peut-elle aider à prévenir des complications liées à la douleur ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une évaluation régulière avec l'EVA peut prévenir des complications comme la chronicité de la douleur." } }, { "@type": "Question", "name": "Comment l'EVA aide-t-elle à identifier des complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "L'EVA permet de détecter des variations de douleur, signalant des complications potentielles." } }, { "@type": "Question", "name": "L'EVA est-elle utile pour évaluer des complications postopératoires ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'EVA est essentielle pour évaluer la douleur et les complications après une chirurgie." } }, { "@type": "Question", "name": "Quelles complications psychologiques peuvent être évaluées par l'EVA ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "L'EVA peut aider à identifier des complications psychologiques comme l'anxiété liée à la douleur." } }, { "@type": "Question", "name": "Quels facteurs de risque influencent l'évaluation de la douleur ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'âge, le sexe et l'état de santé général peuvent influencer l'EVA." } }, { "@type": "Question", "name": "L'EVA prend-elle en compte les différences culturelles ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'EVA peut être influencée par des perceptions culturelles de la douleur." } }, { "@type": "Question", "name": "Comment le stress affecte-t-il l'EVA ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut augmenter la perception de la douleur, influençant les résultats de l'EVA." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils l'EVA ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de douleurs chroniques peuvent affecter les résultats de l'EVA." } }, { "@type": "Question", "name": "L'EVA est-elle sensible aux facteurs psychologiques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs comme l'anxiété et la dépression peuvent influencer les scores de l'EVA." } } ] } ] }

Sources (5076 au total)

Phenotypic Expression of Known and Novel Hemoglobin A2-Variants, Hemoglobin A2-Mae Phrik [Delta 52(D3) Asp > Gly, HBD:c.158A > G], Associated with Hemoglobin E [Beta 26(B8) Glu > Lys, HBB:c.79G > A] in Thailand

The interactions of δ-globin variants with α- and β-thalassemia or other hemoglobinopathies cause complex thalassemic syndromes and potential diagnostic problems. Understanding the molecular basis and...

Clinical Efficacy and Safety of Early Intravenous Administration of Beta-Blockers in Patients Suffering from Acute ST-Segment Elevation Myocardial Infarction Without Heart Failure Undergoing Primary Percutaneous Coronary Intervention: A Study-Level Meta-Analysis of Randomized Clinical Trials.

Several clinical studies have produced diverse results regarding the efficacy and safety of early intravenous beta-blockers in patients with acute ST-segment elevation myocardial infarction (STEMI). A... A database search was conducted using PubMed, EMBASE, the Cochrane Library, and Clinicaltrials.gov for randomized clinical trials (RCTs) that compared intravenous beta-blockers versus placebo or routi... Seven RCTs with 1428 patients were included in this study, with 709 patients in the intravenous beta-blockers and 719 in the control group. Intravenous beta-blockers improved MSI compared to the contr... Intravenous beta-blockers improved the MSI, decreased the risk of VT/VF in the first 24 h, and were associated with increased LVEF at 1 week and 6 months following PCI. In particular, intravenous beta...

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.

AZD2816 is a variant-adapted COVID-19 vaccine that expresses the full-length SARS-CoV-2 beta variant spike protein but is otherwise similar to AZD1222 (ChAdOx1 nCoV-19). This study aimed to evaluate t... In this phase 2/3, randomised, multinational, active-controlled, non-inferiority, immunobridging study, adult participants previously unvaccinated for COVID-19 were enrolled at 16 study sites in Brazi... Between July 7 and Nov 12, 2021, 1449 participants were assigned to the AZD1222 group (n=413), the AZD2816 (4-week) group (n=415), the AZD1222-AZD2816 group (n=412), and the AZD2816 (12-week) group (n... Primary series of AZD1222 and AZD2816 were well tolerated, with no emergent safety concerns. Both vaccines elicited robust immunogenicity against beta and ancestral SARS-CoV-2 with greater responses d... AstraZeneca....

Review of concerned SARS-CoV-2 variants like Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529), as well as novel methods for reducing and inactivating SARS-CoV-2 mutants in wastewater treatment facilities.

The coronavirus known as COVID-19, which causes pandemics, is causing a global epidemic at a critical stage today. Furthermore, novel mutations in the SARS-CoV-2 spike protein have been discovered in ...

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.

This study aimed to evaluate AZD2816, a variant-updated COVID-19 vaccine expressing the full-length SARS-CoV-2 beta (B.1.351) variant spike protein that is otherwise similar to AZD1222 (ChAdOx1 nCoV-1... This phase 2/3, partly double-blinded, randomised, active-controlled study was done at 19 sites in the UK and four in Poland. Adult participants who had received a two-dose AZD1222 or mRNA vaccine pri... Between June 27 and Sept 30, 2021, 1394 participants of the 1741 screened were randomly assigned to AZD1222 or AZD2816 following an AZD1222 (n=373, n=377) or mRNA vaccine (n=322, n=322) primary series... Both boosters were well tolerated, with immunogenicity against ancestral SARS-CoV-2 similar to AZD1222 primary-series vaccination. AZD2816 gave greater immune responses against beta versus AZD1222.... AstraZeneca....

Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol.

Type 1 diabetes (T1D) is an autoimmune disease leading to the destruction of the insulin-producing beta cells resulting in insulin deficiency and hyperglycaemic. Today, no approved therapy exists to h... Individuals ≥12 and <29 years recently diagnosed with T1D (<6 months) will be screened for the HLA DR3-DQ2 haplotype, endogenous insulin production estimated by fasting C-peptide and presence of GAD65... The trial is approved by Ethics Committees in Poland (124/2021), the Netherlands (R21.089), Sweden (2021-05063), Czech Republic (EK-1144/21), Germany (2021361) and Spain (21/2021). Results will be pub... EudraCT identifier: 2021-002731-32, NCT identifier: NCT05018585....